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Abstract
Background: Diabetic dyslipoproteinemia is characterized by hypertriglyceridemia, low HDL-
cholesterol and often elevated LDL-cholesterol and is a strong risk factor for atherosclerosis.
Adhesion molecule levels are elevated both in hyperlipoproteinemia and diabetes mellitus. It is
unclear whether fibrate or statin therapy has more beneficial effects on adhesion molecule
concentrations.
Methods: Atorvastatin (10 mg/d) was compared to fenofibrate (200 mg/d) each for 6 weeks
separated by a 6 week washout period in 11 patients (6 male, 5 female; 61.8 ± 8.2 years; body mass
index 29.8 ± 3.1 kg/m2) with type 2 diabetes mellitus (HbA1c  7.3 ± 1.1 %) and mixed
hyperlipoproteinemia using a randomized, cross-over design. Fasting blood glucose, HbA1c, lipid
parameters, E-selectin, ICAM-1, VCAM-1, and fibrinogen concentrations were determined before
and after each drug.
Results: Glucose and HbA1c concentrations remained unchanged during the whole study period.
LDL cholesterol was reduced during atorvastatin therapy, triglycerides were lowered more
effectively with fenofibrate. Comparison of pre- and postreatment concentrations of E-selectin
showed a reduction during atorvastatin (-7 %, p = 0.11) and fenofibrate (-10 %, p < 0.05) therapy.
Atorvastatin treatment reduced VCAM-1 levels by 4% (p < 0.05), while VCAM-1 concentrations
remained unchanged (+1%, ns) during fenofibate therapy. However, direct comparisons of post-
treatment levels during both forms of therapy were not of statistical significance. ICAM-1 levels
were not influenced by either form of therapy.
Conclusions: In addition to the different beneficial effects on lipid metabolism, both drugs appear
to lower adhesion molecule plasma concentrations in a different manner in patients with type 2
diabetes and mixed hyperlipoproteinemia. Our observations should be confirmed in a larger cohort
of such patients.
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Background
Dyslipoproteinemia in patients with type 2 diabetes mel-
litus is characterized by elevated triglycerides, low HDL
cholesterol and often elevated LDL cholesterol. HMGCoA
reductase inhibitors have been shown to reduce athero-
sclerosis related morbidity and mortality in patients with
diabetes mellitus [1,2]. On the other hand, fibrates are
drugs that can decrease triglyceride concentrations and
increase HDL cholesterol levels. In recent studies it was
shown that they can reduce cardiovascular morbidity and
mortality [3] and progression of coronary heart disease in
patients with type 2 diabetes and hyperlipoproteinemia
[4].
Elevated levels of adhesion molecules in plasma have
been shown to be associated with diabetes mellitus [5]
and dyslipoproteinemia [6-8]. There is strong evidence
that the concentration of intercellular adhesion molecule-
1 (ICAM-1) correlates positively with future cardiovascu-
lar risk in healthy men [9]. In type 2 diabetes, vascular cel-
lular adhesion molecule-1 (VCAM-1) concentrations are
positively correlated to future cardiovascular risk [10]. E-
selectin is thought to indicate endothelial activation [11].
Several trials in patients with hypercholesterolemia
revealed inconsistent results: In one study, HMGCoA
reductase inhibitors lowered E-selectin levels in patients
with hypercholesterolemia [7], another study observed an
ICAM-1 reduction [12]. However, more recent publica-
tions did not confirm these findings and did not show an
influence of statin therapy on adhesion molecule concen-
trations in patients with hyperlipoproteinemia [13,14].
There are few intervention trials which focus on the rela-
tionship between adhesion molecule levels and dyslipi-
demia in patients with diabetes mellitus. In type 2
diabetic patients with poor metabolic control intensive
insulin treatment normalized initially elevated levels of
the adhesion molecules E-selectin and VCAM-1 [5]. Ator-
vastatin therapy for 12 months lowered E-selectin and
VCAM-1 levels in patients with diabetes mellitus and
hypercholesterolemia [15]. The effect of fibrate therapy
on adhesion molecule levels has not been studied yet in
diabetic dyslipoproteinemia.
It is currently unclear from which form of lipid lowering
therapy patients with diabetic dyslipoproteinemia benefit
most. However, we have recently shown that atorvastatin
lowers LDL cholesterol and fenofibrate lowers triglycer-
ides in patients with type 2 diabetes and mixed hyperlipo-
proteinemia. Both drugs reduced total cholesterol and
increased HDL cholesterol [16]. In addition, fenofibrate
induced a beneficial shift in LDL subtype distribution. We
now report the effects of atorvastatin and fenofibrate
administration for 6 weeks on the plasma concentrations
of the adhesion molecules E-selectin, VCAM-1, and
ICAM-1 in these patients with type 2 diabetes mellitus and
mixed hyperlipoproteinemia.
Subjects and Methods
We performed an analysis on the plasma samples of 11
patients of a previously published trial [16]. Unfortu-
nately, one plasma sample was lost for the post hoc anal-
ysis. Therefore, another patient with type 2 diabetic and
mixed hyperlipoproteinemia was recruited.
In brief, 11 non-smoking patients (6 males, 5 females; age
61.8 ± 8.2 years; body mass index 29.8 ± 3.1 kg/m2) with
type 2 diabetes mellitus (duration 12 ± 7 years; hemo-
globin A1c 7.3 ± 1.1 %) and mixed hyperlipoproteinemia
(LDL cholesterol > 130 mg/dL; triglycerides > 200 mg/dL)
without evidence of coronary heart, cerebrovascular,
peripheral arterial disease or either microvascular compli-
cations (i.e. diabetic retinopathy, nephropathy or
polyneuropathy) were included in the study after giving
written informed consent. The study was approved by the
ethics committee of the Ludwig-Maximilians-University
Munich.
The study was designed and performed as a prospective,
randomized, open labeled, cross-over trial. Following a 6-
week wash-out period with no lipid-lowering drug ther-
apy, patients were randomized to receive either 10 mg
atorvastatin or 200 mg fenofibrate daily for 6 weeks. Fol-
lowing another wash-out period of 6 weeks patients were
then crossed to the other arm and received fenofibrate or
atorvastatin, respectively. The effects on lipid concentra-
tions, which have been published previously for all except
one patient are shown in table 1.
Before and after each treatment venous blood was drawn
for laboratory analysis after an overnight fast. Plasma had
been separated within 30 min and was stored at -80°C
until analysis. E-selectin, VCAM-1 and ICAM-1 concentra-
tions were determined from deep-frozen plasma follow-
ing the instructions of a commercially available ELISA kit
(R&D Systems, Wiesbaden, Germany). Absorbance was
measured at 450 nm (Sunrise, TECAN, Crailsheim, Ger-
many). All measurements were done at least twice and in
one assay. The intra-assay coefficient of variability was < 3
% for E-selectin and < 2 % for both VCAM-1 and ICAM-1.
The results are reported as the mean ± standard deviation.
All statistical analyses were performed with SPSS 10.0
(SPSS Software, Munich, Germany). Baseline and post-
treatment concentrations of lipids, fibrinogen, and adhe-
sion molecules as well as their absolute and relative
changes during therapy, respectively, were analyzed for
correlation using the Spearman test. Potential differences
between baseline values before treatment periods (with
either fenofibrate or atorvastatin, respectively) wereCardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/17
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evaluated using co-variance analysis (ANCOVA) [17]. Dif-
ferences between treatments were analyzed using the Wil-
coxon matched-pairs signed-rank test.
Results
The effect of both medications on lipoprotein and fibrin-
ogen concentrations has been described in detail earlier
[16]. In summary (table 1), there were significant reduc-
tions of total cholesterol by 25 % (atorvastatin) and 17 %
(fenofibrate), of LDL cholesterol by 28 % (atorvastatin),
and of triglycerides by 42 % (fenofibrate). While the con-
centration of all LDL subtypes decreased during atorvasta-
tin therapy, small, dense LDL decreased and intermediate
dense LDL increased during fenofibrate therapy. HDL
cholesterol levels increased significantly with both drugs
(+ 15 % and + 14 %). Fibrinogen concentrations were
reduced during fenofibrate treatment only (-19 %). Anti-
diabetic treatment and control of hyperglycemia
remained unchanged during the whole study period as
reflected by similar fasting blood glucose and HBA1c
levels.
There was no difference of adhesion molecule concentra-
tions after the washout periods, respectively. The levels of
the intercellular adhesion molecule-1 (ICAM-1) were not
changed by either drug (table 2). E-selectin was lowered
with borderline significance during atorvastatin treatment
(-7%, p = 0.11), E-selectin reduction during fenofibrate
therapy was statistically significant (-10%, p < 0.05). In
contrast, VCAM-1 levels remained unchanged during
fenofibrate therapy, but were reduced by 4 % during ator-
vastatin treatment (p < 0.05). Direct comparison of post-
treatment values confirmed greater reductions of E-selec-
tin concentrations during fenofibrate therapy and VCAM-
1 levels during atorvastatin therapy. However, these find-
ings were not of statistical significance (p = 0.13 and p =
0.32, respectively).
While the relative reduction in LDL cholesterol during
atorvastatin therapy correlated with the relative reduction
in VCAM-1 (p < 0.05, r = 0.64), we did not observe any
other correlation between either baseline or therapy
induced changes in lipid concentrations with either base-
line or therapy induced changes in adhesion molecule
concentrations. Particularly, there was no correlation of
triglyceride levels and LDL subtype distribution with
adhesion molecule concentrations or their reductions
during both forms of therapy, respectively.
Discussion
The greatest limitation of this study is probably the low
number of participants. However, recruitment of study
patients was very difficult, because patients with macro- or
microvascular complications had to be excluded from this
study for ethical reasons. Unfortunately, medications
were not administered in a placebo-controlled way. This
fact contributes to the weaknesses of this study. Another
limitation of this study consists of the relative shortness of
treatment periods compared to life-long therapy in clini-
cal practice. However, treatment periods had to be rela-
tively short for ethical reasons, because International
Guidelines propagate target values for LDL cholesterol <
100 mg/dl in patients with diabetes mellitus type 2 and
dyslipoproteinemia. This target values were reached only
by a minority of patients during each treatment period.
In addition to the expected changes in lipid concentra-
tions atorvastatin and fenofibrate therapy resulted in dif-
ferential effects on several adhesion molecule plasma
concentrations in diabetic dyslipoproteinemia. The con-
centrations of E-selectin were lowered during atorvastatin
(-7%, ns) and fenofibrate (-10%, p < 0.05) therapy. Ator-
vastatin treatment reduced VCAM-1 levels by 4% (p <
0.05), while VCAM-1 concentrations remained
unchanged (+1%, ns) during fenofibate therapy. ICAM-1
Table 1: Lipoprotein and fibrinogen concentrations during atorvastatin and fenofibrate therapy (n = 11).
atorvastatin fenofibrate
before (mg/dL) during (mg/dL) change (%) before (mg/dL) during (mg/dL) change (%)
Total cholesterol 260 ± 46 193 ± 45 -25*** 270 ± 48 219 ± 26 -17***
Total triglycerides 313 ± 198 210 ± 63 -11 320 ± 190 162 ± 48 -42***
LDL-cholesterol 150 ± 39 108 ± 39 -28** 161 ± 48 142 ± 23 -7
large, buoyant 15.2 ± 7.1 10.8 ± 5.4 -27** 17.8 ± 9.4 14.2 ± 3.6 -10
intermediate 
dense
57.8 ± 25.2 42.8 ± 19.4 -22* 61.8 ± 29.0 75.9 ± 20.2 +31
small, dense 85.9 ± 13.4 57.8 ± 17.5 -23* 91.8 ± 17.8 61.9 ± 19.2 -32*
HDL-cholesterol 46.8 ± 9.4 51.1 ± 10.4 +15* 50.6 ± 12.6 55.1 ± 11.6 +14*
Fibrinogen 406 ± 41 400 ± 41 -1 411 ± 57 329 ± 32 -19**
a: *p < 0.05; **p < 0.01; ***p < 0.005. b: LDL subtypes refer to following density intervals: large buoyant LDL 1.020 – 1.029 g/mL, intermediate 
dense LDL 1.030 – 1.034 g/mL, small dense LDL 1.041–1.066 g/mL. c: The data from 10 out of 11 patients were published previously [16].Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/17
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levels were not influenced by either form of therapy. How-
ever, these reductions were found to be statistically signif-
icant when pre- and post-treatment concentrations of
adhesion molecules were compared. Direct comparison
of post-treatment values for each drug showed a trend for
greater reductions of E-selectin levels during fenofibrate
therapy, and VCAM-1 during atorvastatin therapy, but
these reductions were not of statistical significance.
Two studies evaluating larger cohorts of hypertriglyceri-
demic patients with low HDL cholesterol levels revealed
negative correlations between HDL cholesterol and adhe-
sion molecule levels. However, their findings were not
very conclusive. One study [18] observed decreasing HDL
cholesterol levels were associated with increasing levels of
VCAM-1 and ICAM-1, but not associated with E-selectin
levels. On the other hand, another study [8] did not
observe an association of VCAM-1 levels in patients
groups with high, intermediate, or low HDL cholesterol.
In individuals with HDL cholesterol levels (below the 10th
percentile), this study found an correlation of HDL cho-
lesterol concentrations with ICAM-1 and E-selectin, but
not with VCAM-1. The results of the intervention part of
the last-mentioned study was partly in concordance with
our findings. In a group of 20 non-diabetic patients with
similar lipid profile (i.e. similar triglyceride, LDL and
HDL cholesterol concentrations) fenofibrate therapy led
to a decrease of E-selectin levels [8]. This decrease of E-
selectin was weakly associated with the observed and well-
known increase of HDL cholesterol during fibrate therapy.
Possibly, our study group consisted of too few patients to
confirm this weak association. However, other, lipid-
independent mechanisms of fibrate action seem also
plausible: Fibrates like thiazolidinediones (insulin sensi-
tizer) activate the peroxisome proliferator-acitaved recep-
tor (PPAR) system. Treatment of type 2 diabetes mellitus
with troglitazone led to a reduction of E-selectin levels by
23 % [19]. Thus, common activation of the PPAR system
during both fibrate and glitazone therapy could explain
similar effects on E-selectin levels. Therefore, E-selectin
reduction during fibrate therapy could be a lipoprotein-
independent, i.e. pleiotropic effect of fibrate therapy.
However, during troglitazone treatment the lower E-selec-
tin levels were associated with a lower oxidative suscepti-
bility of LDL cholesterol [19]. Since fenofibrate induces a
shift in LDL subtype distribution from small, dense LDL
to intermediate dense LDL [16], which are less susceptible
to oxidation [20], fenofibrate may also have induced E-
selectin reduction via a beneficial shift in LDL subtype
distribution.
Although E-selectin level reduction during atorvastatin
treatment was not significant in our study, treatment with
HMGCoA reductase inhibitors have reduced E-selectin
levels effectively in hypercholesterolemic patients [7] and
in patients with diabetic dyslipoproteinemia [15]. The
more profound effect on E-selectin concentrations in
these studies might have been mediated by the more pro-
found reduction of LDL cholesterol [7] and the longer
period of treatment [15], respectively. Again, it is also pos-
sible that E-selectin reduction during HMGCoA inhibitor
therapy is mediated by the reduction of small, dense LDL,
because the absolute reductions of small, dense LDL cho-
lesterol were similar during therapies with atorvastatin or
fenofibrate [16]. However, mediation of E-selectin levels
by small, dense LDL appears unlikely because there was
no correlation between baseline levels or relative reduc-
tions of LDL cholesterol and E-selectin levels, respectively.
Moreover, others studies did not demonstrate an influ-
ence of statin therapy on E-selectin concentrations in non-
diabetic patients with hyperlipoproteinemia [12,13].
While ICAM-1 concentrations were not influenced by
either form of lipid lowering therapy in this study, VCAM-
1 concentrations were reduced by atorvastatin only. This
reduction was correlated with LDL cholesterol reduction
(p < 0.05). This finding is consistent with in-vitro studies
which revealed an enhanced VCAM-1 gene expression
during exposure of LDL to endothelial cell culture [21].
The VCAM-1 reduction during atorvastatin therapy con-
firms the findings of Dalla Nora et al. [15], who found an
even more pronounced reduction of VCAM-1 levels after
12 months of treatment.
Thus, the observed changes in adhesion molecule concen-
trations may relate either to changes in lipids, pleiotropic
Table 2: Adhesion molecule concentrations during atorvastatin and fenofibrate therapy (n = 11).
atorvastatin fenofibrate
before (ng/mL) during (ng/mL) change (%) before (ng/mL) during (ng/mL) change (%)
E-Selectin 70.3 ± 37.3 67.5 ± 40.1 -7 71.9 ± 42.5 62.8 ± 33.2 -10*
VCAM-1 779 ± 177 745 ± 166 -4* 752 ± 176 757 ± 161 +1
ICAM-1 285 ± 70 286 ± 69 +1 310 ± 65 296 ± 67 -4
*p < 0.05Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/17
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effects of lipid lowering medications or simply reflect the
fact that there is less active atherosclerosis during lipid
lowering treatment. Changes in lipids may play an impor-
tant role, because we and others [7] observed that some
but not all of the changes in adhesion molecule concen-
trations correlate with the changes in the concentration
and/or lipid composition. Pleiotropic effects of statins,
which have been described in detail elsewhere [22,23]
account for the lipid-independent effects of these drugs
and refer to changes in thrombogenicity, inflammation as
well as arterial myocyte proliferation and migration [23],
and endothelial function [24]. In contrast to the often-dis-
cussed pleiotropic effects of HMGCoA reductase inhibi-
tors, less is known about pleiotropic effects of fibrates.
However, it has been recently shown that fenofibrate low-
ers E-selectin and ICAM-1 concentrations [8] and
improves vascular function in patients with hypertriglyc-
eridemia [25]. It is quite likely that an improvement in
endothelial function will also result in changes in adhe-
sion molecule concentration. Finally, changes in adhesion
molecule concentration may represent less active athero-
sclerosis. This is supported by studies which indicate that
other approaches (i.e. ACE inhibitor therapy) also
decrease adhesion molecule concentrations [26,27]. Our
study was not designed to elucidate the mechanisms link-
ing lipid lowering therapy to changes in adhesion mole-
cule concentration, but it is possible that all of the above
mentioned mechanisms contribute to the observed
changes of plasma levels of E-selectin and VCAM-1.
Although the exact mechanisms remain unclear, there is
no doubt that adhesion molecules are clinically important
in atherosclerosis. E-selectin concentrations indicate
endothelial activation [11] and are higher in diabetics
compared to controls [5,17]. Cardiovascular morbidity
and mortality in type 2 diabetic patients with hyperlipo-
proteinemia can be reduced by lipid lowering therapy
with statins [1,2] or fibrates [3]. It is possible that the
reduction of atherosclerosis in clinical trials is at least
partly due to the reduction of E-selectin levels. VCAM-1
was shown to be associated with cardiovascular mortality
in type 2 diabetics in a recent study [10]. The reduction of
cardiovascular risk during therapy with HMGCoA reduct-
ase inhibitors might be partly represented by VCAM-1
reduction.
Conclusions
The optimal lipid lowering therapy of patients with type 2
diabetes and mixed hyperlipoproteinemia remains an
unsolved problem. The improvements of lipoprotein con-
centrations during either HMGCoA reductase inhibitor
(i.e. mainly LDL cholesterol reduction) or fibrate (triglyc-
eride reduction plus a beneficial shift from small, dense
LDL to intermediate LDL) therapy have been described
elsewhere [16]. Irrespective of the limitations of this
study, our results indicate that in addition to the differen-
tial effects on lipoprotein metabolism, both drugs may
lower adhesion molecule levels in type 2 diabetics with
mixed hyperlipoproteinemia in a different manner, i.e. in
our patients fenofibrate lowered the concentration of E-
selectin, and atorvastatin reduced VCAM-1 levels and
showed a trend to lower E-selectin levels. It would be use-
ful to prove these effects of lipid-lowering therapy on
adhesion molecule concentrations in a larger group of
patients with diabetes mellitus type 2 and mixed hyperli-
poproteinemia, because these effects may contribute to
the beneficial effects of atorvastatin and fenofibrate
therapy.
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